Add BrightSurf on Google Email

Synthetic RIG-I-agonist RNA induces death of hepatocellular carcinoma cells

A synthetic retinoic acid-inducible gene I (RIG-I) agonist RNA has been shown to induce innate immune signaling and death of hepatocellular carcinoma cells in vitro. The addition of recombinant interferon-b potentiated this cell death, suggesting a potential new mechanism for treating patients with liver cancer.

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalJournal of Interferon & Cytokine Research·TypeExperimental study·DateFeb 19, 2025
SAMSUNG T9 Portable SSD 2TB

SAMSUNG T9 Portable SSD 2TB transfers large imagery and model outputs quickly between field laptops, lab workstations, and secure archives.

Beyond the gut: A new frontier in IBS treatment by targeting the brain

Researchers at Tokyo University of Science have found that opioid delta-receptor agonists can alleviate stress-induced IBS symptoms in a validated mouse model by targeting the central nervous system. The study suggests that these drugs could provide a more definitive solution for IBS with minimal adverse effects.

SourceTokyo University of Science·JournalBritish Journal of Pharmacology·TypeExperimental study·DateFeb 5, 2025

Age and sex differences in efficacy of treatments for type 2 diabetes

A systematic review and network meta-analysis of 601 trials revealed that SGLT2 inhibitors were more cardioprotective in older adults, while GLP-1 receptor agonists offered greater benefits to younger patients. These findings suggest personalized treatment approaches for type 2 diabetes based on age and sex.

SourceJAMA Network·JournalJAMA·DateFeb 3, 2025

Longitudinal analysis of obesity drug use and public awareness

The study found a significant increase in obesity drug prescriptions from 0.76 million in July 2017 to 1.5 million in February 2024, mirroring rising public online search activity for semaglutide and tirzepatide. This correlation highlights the real-time association between public awareness and prescription trends.

SourceJAMA Network·JournalJAMA Network Open·DateJan 29, 2025

Doctors test a new way to help people quit fentanyl

A new microdosing approach using low doses of buprenorphine has been tested on patients with opioid use disorder, but most found it ineffective. The study, which included 126 participants, showed that only 34% were able to work up to a full dose of buprenorphine.

SourceUniversity of California - San Francisco·JournalJAMA Network Open·DateJan 24, 2025
Apple iPhone 17 Pro

Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.

Online advertising of compounded glucagon-like peptide-1 receptor agonists

A cross-sectional study found that websites selling compounded glucagon-like peptide-1 receptor agonists often misinformed potential consumers about the medications' safety, efficacy, and FDA approval status. The study highlights the need for increased transparency and regulation in the online advertising of these medications.

SourceJAMA Network·JournalJAMA Health Forum·DateJan 17, 2025

Scientists uncover rapid-acting, low-side-effect antidepressant target

A new study reveals that delta opioid receptor agonist KNT-127 has a rapid and effective antidepressant effect with minimal side effects. The research highlights the molecular mechanisms underlying its action, including mTOR signaling pathways and Akt activation in the medial prefrontal cortex.

SourceTokyo University of Science·JournalMolecular Psychiatry·TypeExperimental study·DateJan 14, 2025
Anker Laptop Power Bank 25,000mAh (Triple 100W USB-C)

Anker Laptop Power Bank 25,000mAh (Triple 100W USB-C) keeps Macs, tablets, and meters powered during extended observing runs and remote surveys.

Risk of thyroid cancer among GLP1-RA users

A large international study of GLP1-RA users and dipeptidyl peptidase-4 inhibitors (DPP-4i) found no evidence that GLP1-RA use is associated with an increased risk of thyroid cancer. The study, published in the Thyroid journal, analyzed data from 92,497 GLP1-RA users and 2,484,408 DPP-4i users.

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalThyroid·TypeObservational study·DateJan 8, 2025

Changes in adult obesity trends in the US

Adult obesity trends in the US have declined for the first time in more than a decade, according to recent data. The South region experienced the largest decreases in body mass index and obesity prevalence, despite also facing high COVID-19 mortality rates among obese individuals.

SourceJAMA Network·JournalJAMA Health Forum·DateDec 13, 2024

Alcohol use and antiobesity medication treatment

A cohort study found that nearly half of participants who consumed alcohol at baseline decreased their alcohol use after initiating anti-obesity medication treatment. The medications, such as naltrexone and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), may have properties that lead to reduced cravings for alcohol.

SourceJAMA Network·JournalJAMA Network Open·DateNov 26, 2024
Celestron NexStar 8SE Computerized Telescope

Celestron NexStar 8SE Computerized Telescope combines portable Schmidt-Cassegrain optics with GoTo pointing for outreach nights and field campaigns.

Novel immunotherapy combo shows promise in melanoma

A phase 2 clinical trial found that the combination of vidutolimod and nivolumab led to tumor control in 55% of patients, with higher levels of immune-related proteins detected in responders. The study also uncovered unique signatures of TLR9 activation and a link between gut microbiome and response to therapy.

SourceUniversity of Pittsburgh·JournalCancer Cell·TypeRandomized controlled/clinical trial·DateNov 1, 2024
Creality K1 Max 3D Printer

Creality K1 Max 3D Printer rapidly prototypes brackets, adapters, and fixtures for instruments and classroom demonstrations at large build volume.

Ozempic (and similar medications) may be the new treatment for opioid and alcohol use disorder

A new study found that people with opioid or alcohol use disorder who take Ozempic or similar medications have a lower rate of opioid overdose and alcohol intoxication. The medication, which treats diabetes and weight-related conditions, may also alter the brain's reward-response pathways associated with substance use.

SourceSociety for the Study of Addiction·JournalAddiction·TypeObservational study·DateOct 17, 2024

Scientific review reveals top three effective ways to stop smoking

A major review by the Cochrane Tobacco Addiction Group identifies three effective ways to stop smoking: counseling, bupropion, and nicotine replacement therapy. The study found that combining these strategies with behavioral support yields the best results for quitting smoking.

SourceUniversity of Massachusetts Amherst·JournalAddiction·TypeLiterature review·DateSep 4, 2024

GLP-1 receptor agonist use and risk of suicide death

A cohort study found no association between GLP-1 receptor agonist use and increased risk of suicide death or related disorders in patients with type 2 diabetes. The study included mostly patients with type 2 diabetes.

SourceJAMA Network·JournalJAMA Internal Medicine·DateSep 3, 2024
Kestrel 3000 Pocket Weather Meter

Kestrel 3000 Pocket Weather Meter measures wind, temperature, and humidity in real time for site assessments, aviation checks, and safety briefings.

New pancreatic cancer treatment proves effective in shrinking, clearing tumors

Researchers have developed a novel nanoparticle drug-delivery system to activate an immune pathway in combination with tumor-targeting agents, showing promising results in treating pancreatic cancer. Eight out of nine mice tested experienced tumor improvements, including two complete responses.

SourceUniversity of Massachusetts Amherst·JournalScience Translational Medicine·TypeExperimental study·DateAug 28, 2024

Study raises concerns about residential opioid treatment providers in NC

A North Carolina State University study found that only 12% of organizations providing residential opioid substance use services are licensed by the state. Only a quarter allow patients to access proven opioid agonist treatment (OAT), which has better outcomes and cuts overdose deaths in half.

SourceNorth Carolina State University·JournalJournal of Substance Use and Addiction Treatment·TypeSurvey·DateAug 28, 2024

Weight loss drug’s heart benefits extend to people with heart failure

A new study found that semaglutide significantly reduces major adverse cardiac events, including heart attacks and strokes, among overweight individuals with cardiovascular disease. The medication also shows similar benefits for people with pre-existing heart failure, regardless of type or severity.

SourceUniversity College London·JournalThe Lancet·TypeRandomized controlled/clinical trial·DateAug 22, 2024
Sky-Watcher EQ6-R Pro Equatorial Mount

Sky-Watcher EQ6-R Pro Equatorial Mount provides precise tracking capacity for deep-sky imaging rigs during long astrophotography sessions.

Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes

Researchers found GLP-1 receptor agonists lower risks of certain obesity-associated cancers in patients with type 2 diabetes, suggesting potential benefits for cancer prevention in high-risk populations. The study provides preliminary evidence supporting further preclinical and clinical studies to prevent specific obesity-linked cancers.

SourceJAMA Network·JournalJAMA Network Open·DateJul 5, 2024
GoPro HERO13 Black

GoPro HERO13 Black records stabilized 5.3K video for instrument deployments, field notes, and outreach, even in harsh weather and underwater conditions.

One-two punch treatment delivers blood cancer knockout

A novel combination of two existing drugs has been discovered to eradicate AML cancer cells in lab-based tests, offering hope for patients diagnosed annually with the disease. The treatment, pairing venetoclax with a STING agonist, showed high promise in AML samples driven by a mutated p53 protein, a type of AML generally harder to treat.

SourceWalter and Eliza Hall Institute·JournalCancer Cell·TypeObservational study·DateApr 30, 2024
Fluke 87V Industrial Digital Multimeter

Fluke 87V Industrial Digital Multimeter is a trusted meter for precise measurements during instrument integration, repairs, and field diagnostics.

Weight loss and diabetes management drug linked to increased residual gastric content before anesthesia

A study published in JAMA Surgery found that 56% of patients using GLP-1 RAs had significant gastric contents on ultrasound before elective procedures, despite adequate fasting. The study suggests that conventional fasting times may need to be reexamined for this patient subset.

SourceUniversity of Texas Health Science Center at Houston·JournalJAMA Surgery·TypeObservational study·DateMar 6, 2024

How does a diabetes drug lessen symptoms of depression?

Research has shown that dulaglutide, a diabetes drug, can reduce depressive-like behaviors in mice. The study identified four major pathways involved and linked markers of depression to lipid metabolism and tryptophan metabolism. This new perspective may facilitate the use of dulaglutide as a potential therapeutic strategy for depression.

SourceWiley·JournalBrain and Behavior·DateMar 6, 2024
Aranet4 Home CO2 Monitor

Aranet4 Home CO2 Monitor tracks ventilation quality in labs, classrooms, and conference rooms with long battery life and clear e-ink readouts.

New weight loss medication may help lower blood pressure in adults with obesity

A new study published in the American Heart Association journal Hypertension found that tirzepatide significantly lowered systolic blood pressure levels in nearly 500 adults with obesity. The results suggest treating obesity with this weight loss medication may be an effective strategy for preventing or treating high blood pressure.

SourceAmerican Heart Association·JournalHypertension·DateFeb 5, 2024

Few patients receive opioid agonist therapy after opioid overdose, despite benefits

Only 4.1% of hospital encounters for opioid overdoses led to opioid agonist therapy (OAT) initiation within a week of discharge from hospital, highlighting missed opportunities to prevent future mortality and morbidity related to opioid use disorder. Studies show that prompt OAT initiation in the emergency department is crucial to redu...

SourceCanadian Medical Association Journal·JournalCanadian Medical Association Journal·TypeObservational study·DateDec 18, 2023

Nearly 40% of Type 2 diabetes patients stop taking their second-line medication

A Northwestern University study found that nearly two-thirds of patients discontinue or change their medication within a year, highlighting the need for better understanding of barriers to treatment adherence. The high discontinuation rate for GLP-1 RAs may be due to gastrointestinal side effects.

SourceNorthwestern University·JournalThe American Journal of Managed Care·DateDec 12, 2023

Researchers at UC Irvine issue a warning that GLP-1RA’s may be dangerous for children

Researchers at UC Irvine issue a warning that GLP-1RA's may be dangerous for children due to the risk of nutrient imbalance and abuse. The team notes that children need energy and sufficient calories for growth and development, and any change in their diet and exercise balance can have long-term health consequences.

SourceUniversity of California - Irvine·JournalClinical and Translational Science·TypeData/statistical analysis·DateAug 28, 2023
Sony Alpha a7 IV (Body Only)

Sony Alpha a7 IV (Body Only) delivers reliable low-light performance and rugged build for astrophotography, lab documentation, and field expeditions.

USTC unveils 3D structure and molecular mechanism of platelet drug transporter ABCC4

The study reveals the molecular mechanism by which ABCC4 recognizes broad-spectrum substrates, providing a structural basis for rational design of platelet antagonists targeting ABCC4. The research also elucidated the molecular mechanism of ABCC4 in binding and transporting platelet agonists and antagonists.

SourceUniversity of Science and Technology of China·JournalNature Cardiovascular Research·DateJul 28, 2023

Targeting GITR in cancer immunotherapy – there is no perfect knowledge

Researchers discuss the potential of glucocorticoid-induced TNFR-related protein (GITR) as a target for cancer immunotherapy. Preclinical studies have shown potent anti-tumor efficacy, but clinical trials have yielded inconsistent results due to complexities in immune responses and antibody structure.

SourceImpact Journals LLC·JournalOncotarget·TypeCommentary/editorial·DateJun 21, 2023
Apple AirPods Pro (2nd Generation, USB-C)

Apple AirPods Pro (2nd Generation, USB-C) provide clear calls and strong noise reduction for interviews, conferences, and noisy field environments.

Anti-depressant agent KNT-127 reduces stress as well as depression

KNT-127 exhibits anti-stressing and anti-depressant effects in mice, improving social interaction and reducing stress-induced hormone levels. The agent suppresses neuronal inflammation and newborn death without affecting neurogenesis.

SourceTokyo University of Science·JournalNeuropharmacology·TypeExperimental study·DateMay 8, 2023

New mechanisms and therapeutic possibilities for heart failure uncovered by scientists at the Lewis Katz School of Medicine at Temple University and Johns Hopkins University

Researchers at Temple University and Johns Hopkins University found that brain-derived neurotrophic factor (BDNF) loss underlies post-myocardial infarction heart failure. BDNF levels can be replenished therapeutically, abolishing damage to heart tissue and enabling recovery.

SourceTemple University Health System·JournalCirculation Research·DateMar 30, 2023

More than 80% of American adults with type 2 diabetes meet treatment criteria for GLP-1 RAs or SGLT2is but most are not getting them

A study found that over 80% of American adults with type 2 diabetes meet the criteria to use GLP-1 RAs or SGLT2is, but only a small percentage are using them. The medications have a substantially higher cost than current first-line treatments, making it difficult for patients to access them.

SourceAmerican College of Physicians·JournalAnnals of Internal Medicine·TypeData/statistical analysis·DateFeb 27, 2023
GQ GMC-500Plus Geiger Counter

GQ GMC-500Plus Geiger Counter logs beta, gamma, and X-ray levels for environmental monitoring, training labs, and safety demonstrations.

Overweight and obesity prevalent and poorly managed among adults with type 1 diabetes

A recent study found that adults with type 1 diabetes are at a high risk of being overweight or obese, but only half receive lifestyle recommendations to manage their weight. The study also highlighted the importance of individualized patient education in improving weight management for these patients.

SourceAmerican College of Physicians·JournalAnnals of Internal Medicine·TypeData/statistical analysis·DateFeb 13, 2023

Hormone therapy could lower risk of immunotherapy-associated myocarditis in women

A new preclinical study discovered the underlying cause of gender differences in immunotherapy-associated myocarditis and identified potential treatment strategies. Hormone therapies targeting the endocrine-cardiac-immune pathway may reduce this risk without affecting treatment efficacy.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalScience Translational Medicine·DateNov 2, 2022

Obesity prevalence varies significantly for Asian American subgroups

A cross-sectional study of over 70,000 Asian Americans found significant variation in obesity prevalence among subgroups, with Filipino Americans having the highest rate at 28.7% and Chinese Americans the lowest at 13.2%. The study highlights the need for tailored strategies to address obesity disparities among Asian American populations.

SourceAmerican College of Physicians·JournalAnnals of Internal Medicine·TypeData/statistical analysis·DateOct 3, 2022
DJI Air 3 (RC-N2)

DJI Air 3 (RC-N2) captures 4K mapping passes and environmental surveys with dual cameras, long flight time, and omnidirectional obstacle sensing.

Lenabasum, a cannabinoid receptor agonist, is an effective and safe treatment for amyopathic dermatomyositis

Lenabasum has been shown to improve skin symptoms in patients with amyopathic dermatomyositis, demonstrating significant reductions in inflammation and disease severity. The study's findings suggest that lenabasum is a well-tolerated treatment option for refractory skin disease.

SourceElsevier·JournalJournal of Investigative Dermatology·TypeRandomized controlled/clinical trial·DateSep 21, 2022

New drug candidate developed to treat type 2 diabetes

Researchers have combined tesaglitazar and GLP-1 in a new hormone combination for type 2 diabetes treatment, improving glucose metabolism with minimal doses. The new drug has shown promise in animal studies, reducing kidney damage and increasing insulin sensitivity.

SourceDeutsches Zentrum fuer Diabetesforschung DZD·JournalNature Metabolism·TypeExperimental study·DateAug 26, 2022